person · Reporting owner

Stecyk Chrystyna Bedrij

Disclosed activity across 1 company

Tapewire entity: 91077
SEC CIK: 0001811625

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
VACCINEX, INC.VCNX · Entity 9673	Director	May 10, 2024	May 14, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

VACCINEX, INC.

Report date May 10, 2024 · Filed May 14, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75	Direct	10,108	Reported balance After 2024-05-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-10 · Grant · Acquired 10,108 · Balance 10,108 F5: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $829.50	Direct	119	Reported balance Holding disclosure · report date 2024-05-10 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance 119 F1: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $451.50	Direct	136	Reported balance Holding disclosure · report date 2024-05-10 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 136 F2: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $235.20	Direct	253	Reported balance Holding disclosure · report date 2024-05-10 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 253 F3: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.10	Direct	684	Reported balance Holding disclosure · report date 2024-05-10 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 684 F4: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.

Filing footnotes · ownership attribution and instrument terms

F1: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.

F2: This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.

F3: This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.

F4: This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.

F5: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 10, 2024 Filed May 14, 2024 16:32 UTC	VACCINEX, INC. VCNX · Entity 9673	GrantStock Option (Right to Buy) · Derivative	10,108	$0.00 Strike: $5.75	$0.00	Disclosure SEC source: 0001062993-24-010181 · form4.xml · derivative · entry 5 Stecyk Chrystyna Bedrij · CIK 0001811625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,108 Underlying: Common Stock · 10,108 shares Expires not disclosed F5 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. Read SEC document
May 11, 2023 Filed May 15, 2023 16:33 UTC	VACCINEX, INC. VCNX · Entity 9673	GrantStock Option (Right to Buy) · Derivative	143,848	$0.00 Strike: $0.41	$0.00	Disclosure SEC source: 0001062993-23-011116 · form4.xml · derivative · entry 4 Stecyk Chrystyna Bedrij · CIK 0001811625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,848 Underlying: Common Stock · 143,848 shares Expires not disclosed F4 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Read SEC document
May 12, 2022 Filed May 13, 2022 16:46 UTC	VACCINEX, INC. VCNX · Entity 9673	GrantStock Option (Right to Buy) · Derivative	53,254	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001062993-22-012390 · form4.xml · derivative · entry 3 Stecyk Chrystyna Bedrij · CIK 0001811625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,254 Underlying: Common Stock · 53,254 shares Expires not disclosed F3 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. Read SEC document
May 11, 2021 Filed May 12, 2021 16:24 UTC	VACCINEX, INC. VCNX · Entity 9673	GrantStock Option (Right to Buy) · Derivative	28,586	$0.00 Strike: $2.15	$0.00	Disclosure SEC source: 0000891839-21-000137 · edgar.xml · derivative · entry 2 Stecyk Chrystyna Bedrij · CIK 0001811625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Underlying: Common Stock · 28,586 shares Expires not disclosed F2 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. Read SEC document
May 14, 2020 Filed May 18, 2020 16:18 UTC	VACCINEX, INC. VCNX · Entity 9673	GrantStock Option (Right to Buy) · Derivative	25,087	$0.00 Strike: $3.95	$0.00	Disclosure SEC source: 0000891839-20-000117 · edgar.xml · derivative · entry 1 Stecyk Chrystyna Bedrij · CIK 0001811625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,087 Underlying: Common Stock · 25,087 shares Expires not disclosed F1 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.